Similarly, a meta-analysis of 39 randomized controlled trialsincluding 66,478 patients indicated that PCSK9 inhibitors lowered the risk of MIby 20% (95% CI, 14–26%; p< 0.0001), ischemic stroke by 22% (95%CI, 11–33%; p = 0.0005) and coronary revascularization by 17% (95%CI, 11–22%; p< 0.0001) [24]. Here, PCSK9 is linked to ischemic stroke.